Cetuximab (CTX), an anti-EGFR chimeric human-murine monoclonal antibody, has been widely utilized in HNSCC therapy; to date, it remains the only approved targeted therapy (Tathineni et al., 2023). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.